scholarly journals Significance of Abnormal Liver Function Tests in Hemophiliacs: A Follow-Up Study

1977 ◽  
Author(s):  
P.M. Mannucci ◽  
Z.M. Ruggeri ◽  
A. Capitanio ◽  
F. Pareti
Keyword(s):  
Liver Function ◽  
Clinical Evidence ◽  
Liver Function Tests ◽  
Abnormal Liver Function ◽  
Function Tests ◽  
Number Of Patients ◽  
High Incidence ◽  
Therapeutic Measures ◽  
Observation Period

It was previously shown (1) that hemophiliacs have a high incidence of abnormal liver function tests unaccompanied by clinical evidence of illness. Since single measurements are of little use to access the significance of such abnormalities and their possible relationship with chronic hepatitis, hemophiliacs with abnormal liver function tests were regularly followed with measurements carried out at least once a year. 20 patients with raised SGOT-SGPT were followed for up to 3 years; in 9, the abnormalities persisted throughout the whole observation period, whereas in 2 the enzymes were occasionally increased and in 9 they were always normal since the initial abnormal measurement. Out of 39 patients with increased serum gamma-globulins, abnormal values were 1 persistently observed in 11 followed for 3 years. In 28 patients followed for 2 years, persistently abnormal values were found in 21, whereas in 7 normal values were invariably found since the initial abnormal measurement. These findings show that liver function tests are persistently abnormal in a number of patients; in these, biopsy should be considered in order to undertake suitable therapeutic measures.

scholarly journals Abnormal Liver Function Tests and Long-Term Outcomes in Patients Discharged after Acute Heart Failure

2021 ◽  
Vol 10 (8) ◽  
pp. 1730
Author(s):  
Hiroshi Miyama ◽  
Yasuyuki Shiraishi ◽  
Shun Kohsaka ◽  
Ayumi Goda ◽  
Yosuke Nishihata ◽  
...  
Keyword(s):  
Heart Failure ◽  
Liver Function ◽  
Liver Function Tests ◽  
Abnormal Liver Function ◽  
Adverse Outcomes ◽  
Long Term Outcomes ◽  
Function Tests ◽  
Parameter Values

Abnormal liver function tests (LFTs) are known to be associated with impaired clinical outcomes in heart failure (HF) patients. However, this implication varies with each single LFT panel. We aim to evaluate the long-term outcomes of acute HF (AHF) patients by assessing multiple LFT panels in combination. From a prospective multicenter registry in Japan, 1158 AHF patients who were successfully discharged were analyzed (mean age, 73.9 ± 13.5 years; men, 58%). LFTs (i.e., total bilirubin, aspartate aminotransferase or alanine aminotransferase, and alkaline phosphatase) at discharge were assessed; borderline and abnormal LFTs were defined as 1 and ≥2 parameter values above the normal range, respectively. The primary endpoint was composite of all-cause death or HF readmission. At the time of discharge, 28.7% and 8.6% of patients showed borderline and abnormal LFTs, respectively. There were 196 (16.9%) deaths and 298 (25.7%) HF readmissions during a median 12.4-month follow-up period. The abnormal LFTs group had a significantly higher risk of experiencing the composite outcome (adjusted hazard ratio: 1.51, 95% confidence interval: 1.08–2.12, p = 0.017), whereas the borderline LFTs group was not associated with higher risk of adverse events when referenced to the normal LFTs group. Among AHF patients, the combined elevation of ≥2 LFT panels at discharge was associated with long-term adverse outcomes.

scholarly journals Clinical Characteristics, Prognostic Factors, and Real-World Practice of Abnormal Liver Function Tests in Children with Acute Infectious Diseases: A Multicenter Study

2021 ◽  
Author(s):  
Kyung Jae Lee ◽  
Dae Yong Yi ◽  
Yoo Min Lee ◽  
So Yoon Choi ◽  
You Jin Choi ◽  
...  
Keyword(s):  
Liver Function ◽  
Infectious Diseases ◽  
Respiratory Infection ◽  
Real World ◽  
Liver Function Tests ◽  
Abnormal Liver Function ◽  
Function Tests ◽  
Tertiary Teaching ◽  
Common Diagnosis

Abstract Background Abnormal liver function tests (LFTs) are commonly seen in pediatric patients with acute infectious diseases; few studies and no definite clinical guidelines for these conditions are available. This study aimed to elucidate the causes and factors associated with prolongation of liver enzyme elevation. We also investigated actual real-world practices in Korea.Methods A retrospective study was performed on all patients younger than 18 years, who visited six tertiary teaching hospitals around Korea in 2018 for acute infectious diseases and showed alanine aminotransferase (ALT) levels above 60 IU/L. We categorized the infections that cause LFT elevation into six groups: respiratory infection, gastrointestinal infection, urinary tract infection, other febrile disease, Epstein-Barr virus infection, and cytomegalovirus infection. We collected data on the medical specialty of the attending physician who followed up the subject, follow-up duration, percentage of follow-up loss, and their investigation.ResultsA total of 613 patients were enrolled in this study, half of whom (50.7%) were younger than 12 months. The mean initial aspartate aminotransferase and ALT values were 171.2±274.1 and 194.9±316.1 IU/L (range 23~2881, 60~2949 IU/L), respectively; however, other LFTs were within the normal range. Respiratory infection was the most common diagnosis (45.0%), and rhinovirus was the most commonly identified pathogen (9.8%). The follow-up rate was higher with pediatric gastroenterologists (90.5%) and non-gastroenterology pediatricians (76.4%) than with pediatric residents and emergency doctors. Older age was related to better ALT recovery (odds ratio [OR] of age for month was 1.003, with 95% confidence interval [CI] 1.001-1.004, p=0.004), while the number of infection episodes (OR=0.626, 95% CI 0.505-0.777, p<0.001) was associated with poor ALT recovery. Abdominal sonography was the most commonly used diagnostic tool (36.9%), followed by the hepatotropic virus workup. The modalities of hepatitis workup were significantly differently applied by physicians based on their specialties and institutions.Conclusions An LFT abnormality after a systemic infection was common in respiratory infection and under the age of 1 year. Age, number of infections, and initial results of LFTs were related to ALT recovery time. Inter-physician, inter-institution, and inter-specialty variances were observed in real-world practice.

Alpha 1 Anti Trypsin Levels in Asymptomatic Patients with Abnormal Liver Function Tests

Endoscopy ◽  
2006 ◽  
Vol 38 (11) ◽  
Author(s):  
BJ Egan ◽  
S Sarwar ◽  
M Anwar ◽  
C O'Morain ◽  
B Ryan
Keyword(s):  
Liver Function ◽  
Liver Function Tests ◽  
Abnormal Liver Function ◽  
Function Tests ◽  
Asymptomatic Patients

scholarly journals Frequency and Prognostic Significance of Abnormal Liver Function Tests in Patients With Cardiogenic Shock

2017 ◽  
Vol 120 (7) ◽  
pp. 1090-1097 ◽  
Author(s):  
Toni Jäntti ◽  
Tuukka Tarvasmäki ◽  
Veli-Pekka Harjola ◽  
John Parissis ◽  
Kari Pulkki ◽  
...  
Keyword(s):  
Liver Function ◽  
Cardiogenic Shock ◽  
Prognostic Significance ◽  
Liver Function Tests ◽  
Abnormal Liver Function ◽  
Function Tests

Interpretation of Abnormal Liver Function Tests

2014 ◽  
Vol 3 (1) ◽  
pp. e139-e148 ◽  
Author(s):  
Mathew Strasser ◽  
Dushyant Singh
Keyword(s):  
Liver Function ◽  
Liver Function Tests ◽  
Abnormal Liver Function ◽  
Function Tests

Hepatic Safety of Itraconazole

2002 ◽  
Vol 6 (3) ◽  
pp. 210-213 ◽  
Author(s):  
Aditya K. Gupta ◽  
Elisabeth Chwetzoff ◽  
James Del Rosso ◽  
Robert Baran
Keyword(s):  
Liver Function ◽  
Fungal Infections ◽  
Package Insert ◽  
Liver Function Tests ◽  
Pulse Therapy ◽  
Continuous Therapy ◽  
Function Tests ◽  
Published Report ◽  
History Of ◽  
Observation Period

Background: As the use of the newer oral antifungal agents for the treatment of superficial fungal infections becomes more widespread, the issue of safety surrounding their use is becoming an increasingly important consideration. Itraconazole is effective and well tolerated, with most side effects being minor and reversible. The most common adverse events are gastrointestinal upset, headache, and transient skin reaction. There have also been rare reports of hepatitis. Objective: To assess the hepatic safety of pulse and continuous itraconazole in the treatment of onychomycosis. Methods: An analysis was performed on all itraconazole clinical trials sponsored by Janssen Research Foundation in the treatment of onychomycosis, where there was an assessment of laboratory safety. A review of the published literature was also undertaken to assess the hepatic safety of itraconazole in common practice. Results: The data indicate that itraconazole pulse treatment is safe, with no significant differences in the number of code 4 abnormalities (baseline value is in the normal range and at least two values, or the last testing in the observation period, exceed twice the upper limit of normal) in the liver function parameters studied: alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase, and total bilirubin. The incidence of all the code 4 abnormalities was below 2%. In the literature there are reports of symptomatic hepatitis with itraconazole continuous therapy but no published report of symptomatic hepatotoxicity using the pulse regimen. Conclusions: Itraconazole pulse therapy for onychomycosis appears to be safe, especially from the perspective of potential liver damage. In the itraconazole package insert liver function tests are recommended for patients receiving continuous itraconazole for periods of time exceeding 1 month. There is no such monitoring requirement for the pulse regimen unless the patient has a history of underlying hepatic disease, the liver function tests are abnormal at baseline, or at any time that there is the development of signs or symptoms suggestive of liver dysfunction.

Sign in / Sign up

Export Citation Format

Share Document